Cargando…

Arsenic trioxide synergistically promotes the antileukaemic activity of venetoclax by downregulating Mcl-1 in acute myeloid leukaemia cells

BACKGROUND: The evasion of apoptosis through dysregulated Bcl-2 family members is a hallmark of leukaemia stem cells (LSCs) in acute myeloid leukaemia (AML). Therefore, targeting Bcl-2 with venetoclax has been suggested as an attractive strategy for inducing apoptosis in AML LSCs. However, the selec...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cho, Hyunsoo, Jang, Ji Eun, Eom, Ju-In, Jeung, Hoi-Kyung, Chung, Haerim, Kim, Jin Seok, Cheong, June-Won, Min, Yoo Hong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2021
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8051086/ https://www.ncbi.nlm.nih.gov/pubmed/33858507 http://dx.doi.org/10.1186/s40164-021-00221-6

Ejemplares similares

Venetoclax enhances DNA damage induced by XPO1 inhibitors: A novel mechanism underlying the synergistic antileukaemic effect in acute myeloid leukaemia
por: Yu, Hanxi, et al.
Publicado: (2022)

DRP1 Inhibition Enhances Venetoclax-Induced Mitochondrial Apoptosis in TP53-Mutated Acute Myeloid Leukemia Cells through BAX/BAK Activation
por: Jang, Ji Eun, et al.
Publicado: (2023)

Metformin exerts a synergistic effect with venetoclax by downregulating Mcl-1 protein in acute myeloid leukemia
por: Zhou, Fang-jiao, et al.
Publicado: (2021)

PB1779: DEVELOPING NOVEL SYNERGISTIC DRUG COMBINATIONS WITH VENETOCLAX IN ACUTE MYELOID LEUKAEMIA
por: Harrigan, R., et al.
Publicado: (2022)

Comparison of the antileukaemic activity of 5 aza-2-deoxycytidine and arabinofuranosyl-cytosine in rats with myelocytic leukaemia.
por: Richel, D. J., et al.
Publicado: (1988)

ULK1 inhibition as a targeted therapeutic strategy for FLT3-ITD-mutated acute myeloid leukemia
por: Hwang, Doh Yu, et al.
Publicado: (2020)

The antileukaemic activity of 5-Aza-2 deoxycytidine (Aza-dC) in patients with relapsed and resistant leukaemia.
por: Richel, D. J., et al.
Publicado: (1991)

Synergistic killing effects of homoharringtonine and arsenic trioxide on acute myeloid leukemia stem cells and the underlying mechanisms
por: Tan, Ming, et al.
Publicado: (2019)

Arsenic Trioxide and Venetoclax Synergize against AML Progenitors by ROS Induction and Inhibition of Nrf2 Activation
por: Hoang, Dinh Hoa, et al.
Publicado: (2022)

Down-regulation of Mcl-1 through GSK-3β activation contributes to arsenic trioxide-induced apoptosis in acute myeloid leukemia cells
por: Wang, Rui, et al.
Publicado: (2012)

Correction to: Synergistic killing effects of homoharringtonine and arsenic trioxide on acute myeloid leukemia stem cells and the underlying mechanisms
por: Tan, Ming, et al.
Publicado: (2019)

Polyphenols as Key Players for the Antileukaemic Effects of Propolis
por: Abubakar, Murtala B., et al.
Publicado: (2014)

The Development and Clinical Applications of Oral Arsenic Trioxide for Acute Promyelocytic Leukaemia and Other Diseases
por: Chin, Lynn, et al.
Publicado: (2022)

Curcumin Synergistically Enhances the Cytotoxicity of Arsenic Trioxide in U266 Cells by Increasing Arsenic Uptake
por: Han, Dingding, et al.
Publicado: (2021)

Synergistic Effects of Arsenic Trioxide and Radiation: Triggering the Intrinsic Pathway of Apoptosis
por: Moloudi, Kave, et al.
Publicado: (2017)

A comparison of the Antileukaemic Effects of Recombinant Human Tumour Necrosis Factor-α and its Muteins on Leukaemia L1210 and Leukaemia P388 in Mice
por: Warzocha, K., et al.
Publicado: (1994)

Belinostat, a potent HDACi, exerts antileukaemic effect in human acute promyelocytic leukaemia cells via chromatin remodelling
por: Valiuliene, Giedre, et al.
Publicado: (2015)

Inhibition of casein kinase 2 sensitizes mantle cell lymphoma to venetoclax through MCL-1 downregulation
por: Thus, Yvonne J., et al.
Publicado: (2022)

Casein and Peptides Derived from Casein as Antileukaemic Agents
por: Ledesma-Martínez, Edgar, et al.
Publicado: (2019)

Management of relapse in acute promyelocytic leukaemia treated with up‐front arsenic trioxide‐based regimens
por: Fouzia, N. A., et al.
Publicado: (2020)

Oral arsenic trioxide for treating acute promyelocytic leukaemia: Implications for its worldwide epidemiology and beyond
por: Kumana, Cyrus R., et al.
Publicado: (2022)

Long‐term remission of extramedullary cutaneous relapse of acute myeloid leukaemia (leukaemia cutis) treated with decitabine‐venetoclax
por: Maravalle, Denise, et al.
Publicado: (2022)

Arsenic Trioxide and Resveratrol Show Synergistic Anti-Leukemia Activity and Neutralized Cardiotoxicity
por: Fan, Yuhua, et al.
Publicado: (2014)

Resveratrol and Arsenic Trioxide Act Synergistically to Kill Tumor Cells In Vitro and In Vivo
por: Zhao, Xiao-Yan, et al.
Publicado: (2014)

A novel NPM1-RARG-NPM1 chimeric fusion in acute myeloid leukaemia resembling acute promyelocytic leukaemia but resistant to all-trans retinoic acid and arsenic trioxide
por: Chen, Xue, et al.
Publicado: (2019)

Synergistic anti-tumor effects of arsenic trioxide and blue LED irradiation on human osteosarcoma
por: Feng, Chao, et al.
Publicado: (2019)

Arsenic trioxide induces apoptosis in the THP1 cell line by downregulating EVI-1
por: ZHOU, LING-YUN, et al.
Publicado: (2014)

Azacytidine sensitizes acute myeloid leukemia cells to arsenic trioxide by up-regulating the arsenic transporter aquaglyceroporin 9
por: Chau, David, et al.
Publicado: (2015)

Venetoclax combination therapy with hypomethylating agents in young adults with relapsed/refractory acute myeloid leukaemia
por: Báez-Gutiérrez, Nerea, et al.
Publicado: (2021)

Combination of arsenic trioxide and Dasatinib: a new strategy to treat Philadelphia chromosome‐positive acute lymphoblastic leukaemia
por: Wang, Tao, et al.
Publicado: (2017)

Selinexor Synergistically Promotes the Antileukemia Activity of Venetoclax in Acute Myeloid Leukemia by Inhibiting Glycolytic Function and Downregulating the Expression of DNA Replication Genes
por: Jiang, Jiqian, et al.
Publicado: (2023)

PERK/NRF2 and autophagy form a resistance mechanism against G9a inhibition in leukemia stem cells
por: Jang, Ji Eun, et al.
Publicado: (2020)

MicroRNA-204 Potentiates the Sensitivity of Acute Myeloid Leukemia Cells to Arsenic Trioxide
por: Wang, Zhiguo, et al.
Publicado: (2019)

Synergistic efficacy of homoharringtonine and venetoclax on acute myeloid leukemia cells and the underlying mechanisms
por: Yuan, Fangfang, et al.
Publicado: (2022)

Identification of Small‐Molecule Inhibitors of the Antiapoptotic Protein Myeloid Cell Leukaemia‐1 (Mcl‐1)
por: Beekman, Andrew M., et al.
Publicado: (2015)

Arsenic Trioxide for Treating Acute Promyelocytic Leukaemia: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
por: Ramaekers, Bram L. T., et al.
Publicado: (2018)

Resurrection of Oral Arsenic Trioxide for Treating Acute Promyelocytic Leukaemia: A Historical Account From Bedside to Bench to Bedside
por: Kumana, Cyrus R., et al.
Publicado: (2020)

The MCL1-specific inhibitor S63845 acts synergistically with venetoclax/ABT-199 to induce apoptosis in T-cell acute lymphoblastic leukemia cells
por: Li, Zhaodong, et al.
Publicado: (2018)

Arsenic trioxide inhibits tumor-induced myeloid-derived suppressor cells and enhances T-cell activity
por: Gao, Qingmin, et al.
Publicado: (2017)

Arsenic Trioxide and Thalidomide Combination Induces Autophagy Along with Apoptosis in Acute Myeloid Cell Lines
por: Mohammadi Kian, Mahnaz, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_42n1504162rft5c1dvac5jlp5b